# Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model

> **NCT07503405** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Traws Pharma, Inc.** · enrollment: 165 (estimated)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** TRX-100
- **DRUG:** Placebo
- **BIOLOGICAL:** Influenza A/France/759/2021 (H1N1) virus

## Key facts

- **NCT ID:** NCT07503405
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2026-11
- **Final completion:** 2027-04
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07503405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07503405, "Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07503405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*